July 30, 2021 - ROSEN LOGO.jpg
BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
03 nov. 2021 18h45 HE | The Rosen Law Firm PA
NEW YORK, Nov. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
08 avr. 2021 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
14 mai 2020 07h00 HE | uniQure Inc.
~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Feasibility of...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
04 févr. 2020 07h00 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
03 sept. 2019 07h00 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure to Participate in Multiple Upcoming Industry Conferences
26 juil. 2019 07h00 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
30 avr. 2018 12h00 HE | uniQure Inc.
New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 30, 2018 (GLOBE NEWSWIRE) --...